KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

Writing Committee for the HEALEY ALS Platform Trial, Jinsy Andrews, Sabrina Paganoni, Eric A Macklin, Lori B Chibnik, Melanie Quintana, Benjamin R Saville, Michelle A Detry, Matteo Vestrucci, Joseph Marion, Anna McGlothlin, Eufrosina Young, Marianne Chase, Lindsay Pothier, Brittney Harkey, Hong Yu, Alex Sherman, Jeremy Shefner, Meghan Hall, Gale Kittle, Mariah R Connolly, James D Berry, Derek D'Agostino, Eric Tustison, Elisa Giacomelli, Erica Scirocco, Gustavo Alameda, Eduardo Locatelli, Doreen Ho, Adam Quick, Daragh Heitzman, Senda Ajroud-Driss, Stanley H Appel, Sheetal Shroff, Jonathan Katz, Kevin Felice, Nicholas J Maragakis, Zachary Simmons, Stephen A Goutman, Nicholas Olney, Timothy Miller, Joseph Americo Fernandes, Hristelina Ilieva, Omar Jawdat, Michael D Weiss, Laura Foster, Tuan Vu, Shafeeq Ladha, Margaret Ayo Owegi, Daniel S Newman, Ximena Arcila-Londono, Carlayne E Jackson, Andrea Swenson, Terry Heiman-Patterson, James Caress, Dominic Fee, Amanda Peltier, Richard Lewis, Jeffrey Rosenfeld, David Walk, Kristin Johnson, Matthew Elliott, Edward J Kasarskis, Seward Rutkove, Courtney E McIlduff, Richard Bedlack, Lauren Elman, Namita A Goyal, Kourosh Rezania, Paul Twydell, Michael Benatar, Jonathan Glass, Jeffrey A Cohen, Vovanti Jones, Lindsay Zilliox, James P Wymer, Said R Beydoun, Jaimin Shah, Gary L Pattee, Jennifer Martinez-Thompson, Shakti Nayar, Volkan Granit, Mary Donohue, Katheryn Grossman, Daniel J Campbell, Irfan A Qureshi, Merit E Cudkowicz, Suma Babu

JAMA Neurol 82(4) 333-343

PMID40067754
PMCIDPMC11833655
DOI10.1001/jamaneurol.2024.5249
发表日期2025-03-11
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced neuroinflammation and oxidative stress. OBJECTIVE: To determine the safety, tolerability, and efficacy of verdiperstat, a selective myeloperoxidase inhibitor, in ALS. DESIGN SETTINGS AND PARTICIPANTS: Verdiperstat was tested as a regimen of the HEALEY ALS Platform Trial, a multicenter, double-blind, perpetual platform design, randomized clinical trial, with sharing of trial infrastructure and placebo data across multiple regimens. The study was conducted at 54 ALS referral centers across the US from July 2020 to April 2022. Adult participants with a diagnosis of clinically possible, probable, laboratory-supported probable, or definite ALS defined by the revised El Escorial criteria were randomized to verdiperstat or regimen-specific placebo. An additional group of participants concurrently randomized to placebo from other regimens was included in the analyses. INTERVENTIONS: Eligible participants were randomized in a 3:1 ratio to receive oral verdiperstat, 600 mg, twice daily or matching placebo for a planned placebo-controlled duration of 24 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was change from baseline through week 24 in disease severity, as measured by a joint model of ALS Functional Rating Scale-Revised and survival, with the treatment effect quantified by the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression of verdiperstat relative to placebo. RESULTS: A total of 167 participants (mean [SD] age, 58.5 [11.4] years; 59 [35.3%] female; 108 [64.6%] male) were randomized to either verdiperstat (126 [75.4%]) or to placebo (41 [25.6%]). Among the participants randomized to the verdiperstat regimen, 130 (78%) completed the trial. The estimated DRR was 0.98 (95% credible interval, 0.77-1.24; posterior probability = 0.57 for slowing of disease progression [DRR <1]). Verdiperstat was estimated to slow progression by 2% vs placebo (95% credible interval, -23% to 24%; posterior probability 0.57). Verdiperstat was overall safe and well tolerated. Common adverse events in the verdiperstat group were nausea, insomnia, and elevated thyrotropin levels. CONCLUSIONS AND RELEVANCE: Results demonstrate that treatment with verdiperstat was unlikely to alter disease progression in ALS. TRIAL REGISTRATION: Clinical Trial Identifiers: NCT04297683 and NCT04436510.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Change in Disease Severity Over 24 Weeks as Measured by Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) and Survival (Primary Outcome) A, Box plots of the ALSFRS-R change from baseline over time for the active treatment, the regimen placebo, and the shared placebo. Points are the raw mean values at each visit. The solid lines are the model-estimated change in ALSFRS-R over time, adjusting for covariates. The estimate for the placebo regimen shares information from participants receiving placebo in other regimens. The numbers below the panel show the number of participants with known ALSFRS-R outcomes at each visit. The summary excludes all ALSFRS-R data from participants who died or had a death-equivalent event (PAV). B, Kaplan-Meier curves for death/PAV per arm and the model estimated exponential curves for the active treatment and pooled placebo. The numbers below the panel indicate the number of participants exposed and the number of death/PAV events per arm.

B

Mortality probability

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Consolidated Standards of Reporting Trials (CONSORT) Diagram Participants could have multiple reasons for exclusion from the master protocol and could screen for the master protocol more than once. The most common reasons for exclusion were as follows: (1) not meeting the criterion for slow vital capacity ≥50% (61/127 [48% of person-visits]), (2) having a clinically significant unstable medical condition (other than amyotrophic lateral sclerosis [ALS]) that would pose a risk to the participant (36/127 [28% of person-visits]), and (3) having used investigational treatments for ALS within 5 half-lives (if known) or 30 days (whichever is longer) before the master protocol screening visit (24/127 [19% of person-visits]). The 122 participants randomized to placebo included both the 81 from other regimens and the 41 randomized to placebo in this regimen.
非 KM Figure